astrazeneca cardiovascular pipeline

Jernberg T, et al. We encourage you to read the privacy policy of every website you visit. (2019). 's AZN stock has rallied 11.9% this year so far, outperforming the industry's rise of 3.7%. Sacco et al. Circulation. Eur Heart J. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. Around one in three patients with acute coronary artery disease (CAD) is estimated to have type-2 diabetes (T2D), and patients with both CAD and diabetes are at almost double the risk for a major adverse cardiovascular event compared to diabetes patients with only risk factors for cardiovascular disease.6,7, In addition, the more risk factors that a patient with a prior heart attack may have – such as diabetes, multivessel disease or chronic kidney disease – the greater the chance of experiencing an event.8, In the US, about 33-46% of the patients with end-stage renal disease have cardiovascular disease (CVD) and about 28-44% have heart failure.9 The presence of CVD is associated with worsening short and long-term survival of end-stage kidney disease patients after a cardiovascular procedure with CVD being a leading cause of death in those patients.10. Learn more about patients living with chronic kidney disease. We are AstraZeneca, one of the world’s most forward-thinking and connected BioPharmaceutical companies. Knuuti J et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study). Today, we strive to meet even greater expectations by offering options for patients and healthcare providers. Grants and Donations may be awarded to Healthcare Organisations, Patient Organisations, or … 2019]. AstraZeneca has sales in 67 countries in scope. doi:10.1097/MED.0000000000000074. June 2019. (Monday to Friday, 8 AM to 6 PM ET, excluding holidays. AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration. If you are in the US and would like additional information regarding AstraZeneca drugs, please contact the Information Center at AstraZeneca at 1-877-893-1510 1-877-893-1510. National Institutes of Health [cited 2018 Aug 28]. Prevention: Heart attack. … The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastroenterology and systemic eosinophilic-driven diseases. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed. Available from URL: Healthtalk.org. I have read this warning and will not be using any of the contained product information for clinical purposes. We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life. United States Renal Data System. Our country sites can be located in the AZ Network. COVID-19 is caused by a virus called coronavirus (SARS CoV 2). DGK Pressemitteilung, 25. The acquisition continues AstraZeneca’s track record of targeted business development with a focus on three main therapy areas. Through an agile approach, multidisciplinary team and unique organisational structure, OBI is paving the way for innovative research. I have read this warning and will not be using any of the contained product information for clinical purposes. 6. 3. American Heart Association. Available from: URL: https://www.usrds.org/2018/view/v2_08.aspx. Healthy Heart Africa is committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) in Africa. Up to one in five people who have been event-free for a year may experience another heart attack within three years of the first.10 Working together with healthcare professionals, we help raise awareness of the importance of secondary prevention among heart attack survivors. 5. To tackle key issues in cardiovascular care and associated complications, AstraZeneca has entered a multi-year partnership with World Heart Federation (WHF), the world’s leading voice for cardiovascular health. Nakatani D, et al. This website is intended for people seeking information on AstraZeneca's worldwide business. This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. With a strong purpose, an even stronger bond between each of our people and a science-led, patient-first attitude, we’re changing the future of medicine and the … The Global Economic Burden of Non-communicable Diseases. 2. 2019. The Patient Navigator Program is a transition-care improvement initiative implemented in 35 US hospitals designed to reduce the 30-day all-cause readmission rate following hospitalised heart failure, improving patients’ long-term outcomes,19 which may also lead to reduction of regulatory penalties and optimised financial results for hospitals. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas. 10. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. World Heart Day. Our focus is to transform the lives of the millions of patients living with metabolic diseases. Respiratory is one of AstraZeneca’s three main therapy areas. Since launching in Kenya in 2014, then Ethiopia in 2016, Tanzania in 2018 and Ghana in 2019, we have conducted over 11 million blood pressure screenings; identified over 2 million elevated readings; trained over 5,800 healthcare workers; and activated over 700 healthcare facilities.12 In support of the United Nations targets to reduce the risk of premature death from NCDs,13 we aspire to reach 10 million people with elevated blood pressure across Africa by 2025. Lindholm D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Lancet 2016; 388(10053):1459–544. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management. 13. Visit keeptreating.com to learn about the journey of those who want to avoid experiencing a heart attack. An exciting and balanced pipeline underpinned by great science. We are exploring treatment options to reduce cardiovascular problems and death in high-risk patients, beyond acute coronary syndrome. AstraZeneca are also developing testicular cancer drug Lynparza which has had positive findings from trials. 1. 2014 August ; 21(4): 279–286. Available from URL: Di Palo KE, et al. World Health Organization. Presented at: ESC Congress 2018, 2018 Aug 25-29, Munich, Germany. Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Circulation 2016; 133:e674-e690. Entering a new era in vascular and cardiac regeneration research As we move novel therapeutic modalities from the laboratory into clinical trials, we are focusing on the repair and regeneration of tissues with the potential to treat life threatening cardiovascular diseases such as heart failure. Eur Heart J. Supported by the American Heart Association (AHA) and AstraZeneca, One Brave Idea (OBI) aims to understand the molecular events surrounding the earliest transition from wellness to disease in coronary heart disease (CHD). ... Area under investigation:cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Measuring blood flow changes in coronary arteries aids application of targeted heart disease therapies to improve patient outcomes, Hope for CKD: Proactive Prevention and Detection Strategies, Making chronic kidney disease a policy priority, Understanding the journey of care for patients with cardiovascular, renal and metabolic disease, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease, https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395, Accepted Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108. Cardiovascular AstraZeneca has been driving cardiovascular innovation for more than 100 years. J Am Coll Cardiol. R.L. 7. Remarkably, however, AstraZeneca has the third largest pipeline. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, … Our culture at AstraZeneca. Our focus is to transform the lives of the millions of patients living with metabolic diseases. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. Bjornstad et al. For all Medical Information enquiries, about the AstraZeneca COVID-19 vaccine and to view the Information for UK Vaccine Recipients and Information for Healthcare Professionals please click here.. Veeva ID: Z4-25396Date of next review: August 2022. CCC was founded to address the treatment compliance gap, enabling new benchmarks to be set in cardiovascular care. Diabetes Obes Metab 2018; 20(8):2000–3. Pipeline. Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. Cardiovascular disease. Kidney Disease Statistics for the United States: December 2016. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Important notice for users We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. This website is intended for people seeking information on AstraZeneca's worldwide business. our approach towards holistic care for CVRM patients, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.usrds.org/2018/view/v2_08.aspx, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack/lifestyle-changes-for-heart-attack-prevention, https://www.nhs.uk/conditions/heart-attack/prevention/, http://www.healthtalk.org/peoples-experiences/heart-disease/heart-attack/coping-emotions-after-heart-attack, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack, http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf, https://dgk.org/pressemitteilungen/2019-jahrestagung/2019-jt-statements/2019-jt-statements-tag2/neues-versorgungsforschungsprojekt-gullive-r-zur-langzeitversorgung-von-herzinfarkt-patienten-in-deutschland/, Manage other cardiovascular, renal and metabolic diseases and associated risk factors. AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. United States Renal Data System. Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020. AstraZeneca provides this link as a service to website visitors. This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. Chronic kidney disease occurs in the context of multiple comorbidities and has been termed as a “disease multiplier.”11 We work to find ways to help patients manage the many complications and provide solutions for better disease management. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed.4,5 Atherosclerotic plaque, a build-up of deposits of fatty material, cholesterol, cellular waste products and other substances, accumulate in the coronary arteries, obstructing the blood flow to the heart muscle.5 The plaque can cause a partial or complete blockage of blood supply to the heart muscle, which can cause a heart attack.4,5, We are seeing that patient therapy goes beyond treating one disease. April 2019. Up to 94% of people with type-2 diabetes in the US have at least one additional CVRM condition.7 We work to provide solutions for these complications that might become life-threatening, to change the lives of type-2 diabetes patients by reducing risk factors through early prevention. cardiovascular and metabolic diseases. 2015;36(19):1163–70. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. AstraZeneca has a total of 79 R&D projects featuring a small-sized priority R&D pipeline compared to its peers: 4 projects. 2013;77(2):439-46. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. 9. 2010;304(12):1350-7. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. AstraZeneca has said that they’re aware of 15 events of deep vein thrombosis and 22 events pulmonary embolisms, but that’s in 17 million people who have had at least one shot – … AstraZeneca data on file. Available at. Heart failure drug Farxiga has just received approval from the FDA, providing the potential to treat million of people in the United States. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. I am currently leading the global research and early development group for Cardiovascular, Renal and Metabolism (CVRM) in BioPharmaceuticals R&D at AstraZeneca. Available from URL: American Heart Association. LONDON, UK I March 25, 2020 I AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small … In our first co-initiative with WHF, we are supporting people with cardiovascular disease and its complications who are at a higher risk of severe complications of COVID-19 by providing them with the much-needed advice and resources on their risk and how to manage their condition and stay healthy during the pandemic. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. [online] Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ [Accessed 31 Jul. Circ J. Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054. Arnold SV et al. AstraZeneca UK aims to support local innovation and best practice that improves patient care in Respiratory, Immunology, Cardiovascular, Metabolic, Renal and Oncology therapy areas. Veeva ID: Z4-25396Date of next review: August 2022. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Chapter 9: Cardiovascular Disease in Patients With ESRD; 2018. The Euro Heart Survey on diabetes and the heart. AstraZeneca is not responsible for the privacy policy of any third party websites. 2015;132(10):923–31. Eur Heart J 2015; 36:1163-1170. OBI is turning its focus upstream and seeking out earlier changes in the development of CHD, working outside the constraints of traditional biomedical science. Available from URL: Bhatt DL, et al. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization. 11. 2018. Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets). Geneva, Switzerland: World Economic Forum (cited 2018 Aug 6). 2010;31(22):2755-64. Prog Cardiovasc Dis. Zeymer, U. We encourage you to read the privacy policy of every website you visit. Our advanced approach to Regulatory means we are leading the field. Senior Vice President, CVRM, BioPharmaceuticals Business Unit, SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D. American Heart Association. Our 40-year heritage in respiratory medicines is just the beginning of our story. Heart attack. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. 8. 2015. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Chapter 9: Cardiovascular Disease in Patients With ESRD. Since 2014, there has been a 75% compliance rate among those hospitals involved. Curr Opin Endocrinol Diabetes Obes. Heart attack and unstable angina pectoris, are responsible for almost half of all deaths related to cardiovascular disease worldwide. The other 75 R&D projects target other diseases in scope. 2016. Available at:  https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed July 2019. AstraZeneca provides this link as a service to website visitors. 12. J Cardiol 2011; 57(1):8–17. Developed with the American College of Cardiology (ACC), the Program successfully reduced the readmission rate among primary HF inpatients by using a patient-tailored approach.19, GULLIVE-R (GUideline adherence and risk assessment after acute myocardiaL infarction in real LIfe in Germany – a quality improVEment and awareness Registry of the German Cardiac Society) is a real-world evidence registry following patients from up to 250 hospitals and office-based centres in Germany for 9 to 18 months post-MI. We strive to prevent heart disease onset, as well as treat and regenerate the heart to help protect millions of people living with heart failure. 2004;25(21):1880–90. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life. Report a Side Effect uk-drugsafety@sanofi.com +44 (0) 800 0902314 (Monday - Friday) Fax: +44 (0) 800 4716122 Please note, we cannot provide medical advice on your symptoms. Association of key risk factors and their combinations on ischemic outcomes in patients with invasively managed myocardial infarction in Sweden. AstraZeneca and Ionis have a strategic alliance focused on leveraging antisense technology to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. Available from: URL: https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Fox KA, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Available from: URL: https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/atherosclerosis. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH). Important notice for users Neues Versorgungsforschungsprojekt GULLIVE-R zur Langzeitversorgung von Herzinfarkt-Patienten in Deutschland. Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults with and without type-2 diabetes (T2D).
astrazeneca cardiovascular pipeline 2021